For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up +1.2% YoY.
The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.
Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are:
In 2020, the COVID-19 crisis put the spotlight on infection control within hospitals and further reinforces the importance of the infection preventionist (IP) in the “new normal” healthcare setting. Non-compliance with INS SOP and modifications of hospital procedures during the peak of the COVID-19 crises is expected to increase CRBSIs. Numerous modifications taking place during COVID-19 such as ...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click here.
SmartTRAK is kicking off 2021 with some exciting new product launches. Click the button to see what we have on tap in the coming months.